Advertisement
Product › Details
Minjuvi® / Monjuvi®
Next higher product group | tafasitamab (MOR208 / XmAb5574) | |
Status | 2020-08-01 registration start | |
Organisation | MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR) | |
Group | MorphoSys (Group) | |
Organisation 2 | Xencor Inc. (Nasdaq: XNCR) | |
Record changed: 2024-02-06 |
Advertisement
More documents for Minjuvi® / Monjuvi®
- [1] MorphoSys AG. (5/3/23). "Press Release: MorphoSys AG Reports First Quarter 2023 Financial Results". Planegg....
- [2] MorphoSys AG. (8/31/22). "Press Release: MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters". Planegg....
- [3] MorphoSys AG. (11/9/21). "Press Release: MorphoSys Announces Departure of Roland Wandeler". Planegg....
- [4] MorphoSys AG. (8/26/21). "Press Release: MorphoSys and Incyte Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Plan...
- [5] MorphoSys AG. (1/6/21). "Press Release: MorphoSys Appoints Sung Lee as Chief Financial Officer". Planegg....
- [6] MorphoSys AG. (12/1/20). "Press Release: Thomas Biegi Joins MorphoSys as Head of Corporate Communications". Planegg....
- [7] MorphoSys AG. (9/30/20). "Press Release: MorphoSys Announces Departure of Jens Holstein, CFO, by Year End 2020". Planegg....
- [8] MorphoSys AG. (8/1/20). "Press Release: FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)". Planegg & Wilmington, DE....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top